H Lundbeck A/S (HLUYY) 28.5200 $HLUYY
Why Chelsea Therapeutics International Ltd. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - 1 hr ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Chelsea Therapeutics , a biopharmaceutical...
Caregivers of People with Schizophrenia Need Support, Not Stigma
Business Wire - Thu May 01, 8:01AM CDT
Despite growing awareness of mental illness nationally, serious mental illnesses, such as schizophrenia, continue to be associated with significant stigma - not just for the person directly affected, but also for the caregiver.(1,2) Caregivers act as advocates, collaborate with treatment team members and often are the main support in the daily life of their loved one with schizophrenia.(3,4) However, results of a recent survey show that caregivers have experienced emotional burden and social isolation as a result of caring for their loved one.
FDA Accepts for Review Otsuka Pharmaceutical and Lundbeck's Supplemental New Drug Application to Expand Abilify Maintena(R) (aripiprazole) Labeling
Business Wire - Wed Apr 30, 8:02AM CDT
Otsuka America Pharmaceutical, Inc. (OAPI) and H. Lundbeck A/S (Lundbeck) today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for the proposed expanded labeling of Abilify Maintena (aripiprazole) for extended-release injectable suspension to support broader use of the drug for treatment of patients in the acute phase of schizophrenia. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of December 7, 2014 to complete its review.
Eli Lilly Beats on Earnings & Revs, Confirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:40PM CST
2014 will be a challenging year for Eli Lilly with two major products - Cymbalta and Evista - facing generic competition this year.
Allergan Slips on Restasis Challenge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 12:50PM CST
Although Allergan's shares slipped slightly on the news regarding Actavis' ANDA, we do not expect generic competition to enter the market any time soon.
The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
PR Newswire - Wed Dec 18, 7:00AM CST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that successfully treat patients with mild and moderate disease, including market leaders GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination Advair/Seretide/Adoair and Merck's leukotriene inhibitor Singulair (montelukast). These leading agents are already beginning to face generic erosion that will lead their sales to decline.
Mood-Altering News From the Pharma Space
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Dec 13, 9:10AM CST
As a longtime critic of Eli Lilly 's R&D and clinical trial management, I can't say I was surprised to see the news that yet another phase 3 drug candidate failed -- this time it was edivoxetine in depression. That stings all the more with...
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psychiatric Disorders - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/pscmg6/psychiatric) has announced the addition of the "Psychiatric Disorders - Pipeline Review, H2 2013" report to their offering. 'Psychiatric Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Scope - A snapshot of the global therapeutic scenario for Psychiatric Disorders. - A review of the Psychiatric Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychiatric Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Psychiatric Disorders. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Psychiatric Disorders pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Boehringer Ingelheim GmbH Dainippon Sumitomo Pharma Co., Ltd. Samyang Corporation H Lundbeck A/S AVANIR Pharmaceuticals Corcept Therapeutics Incorporated Suven Life Sciences Ltd. Angelini Group Snowdon Inc. Critical Pharmaceuticals Limited CoLucid Pharmaceuticals, Inc. GP Pharm, S.A. PsychoGenics, Inc. Omeros Corporation Edison Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ps...sychiatric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Major Depressive Disorder - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vssm4r/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2013" report to their offering. 'Major Depressive Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Major Depressive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Major Depressive Disorder. Scope - A snapshot of the global therapeutic scenario for Major Depressive Disorder. - A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Major Depressive Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson F. Hoffmann-La Roche Ltd. AstraZeneca PLC Eli Lilly and Company Alkermes, Inc. Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Neurocrine Biosciences, Inc. Gedeon Richter Plc. H Lundbeck A/S Laboratoires Pierre Fabre SA Les Laboratoires Servier Shire Plc OPKO Health, Inc. Neuralstem, Inc. Suven Life Sciences Ltd. e-Therapeutics plc Intas Pharmaceuticals Ltd. Angelini Group and many more... For more information visit http://www.researchandmarkets.com/research/vs...depressive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Alzheimer's Disease Report - Pipeline Review
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d9h2c7/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2013" report to their offering. 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Scope - A snapshot of the global therapeutic scenario for Alzheimer's Disease. - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Alzheimer's Disease Therapeutics Development - Click the link below to view the full list of companies - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - United Biomedical, Inc. - Taisho Pharmaceutical Co., Ltd. - Euroscreen S.A. - Applied NeuroSolutions, Inc. - Avineuro Pharmaceuticals, Inc. - Panacea Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - Novartis AG - Isotechnika Pharma Inc. - Samyang Corporation - Aphios Corporation - Alzhyme Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - H Lundbeck A/S - Jeil Pharmaceutical Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier For more information visit http://www.researchandmarkets.com/research/d9h2c7/alzheimers
Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Parkinson's Disease - Pipeline Review, H2 2013 Report Features Players such as Fabre-Kramer Pharmaceuticals, Inc. and Novartis AG
M2 - Wed Aug 07, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fx4cdq/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Parkinson's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Parkinson's Disease. - A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Parkinson's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Amicus Therapeutics, Inc. AstraZeneca PLC Biogen Idec Inc. Boehringer Ingelheim GmbH Curemark, LLC Dart NeuroScience LLC e-Therapeutics plc Elan Corporation, plc GlaxoSmithKline plc H Lundbeck A/S Indus Biotech Private Limited Jeil Pharmaceutical Co., Ltd. KineMed, Inc. Labtec GmbH Merck & Co., Inc. OPKO Health, Inc. Pharmagenesis, Inc. QR Pharma, Inc. Raptor Pharmaceuticals Corp. reMYND Sanofi-Aventis Snowdon Inc. Takeda Pharmaceutical Company Limited UCB Group ViaCord Wellstat Therapeutics Corporation XenoPort, Inc. For more information visit http://www.researchandmarkets.com/research/fx4cdq/parkinsons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psychosis - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and Clera Inc.
M2 - Tue Aug 06, 12:02PM CDT
Research and Markets (http://www.researchandmarkets.com/research/plc8gk/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Psychosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Psychosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Addex Pharmaceuticals Clera Inc. Evotec Aktiengesellschaft H Lundbeck A/S Newron Pharmaceuticals S.p.A. Reviva Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/plc8gk/psychosi About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
General Anxiety Disorder - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bhjrl/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H1 2013" report to their offering. 'General Anxiety Disorder - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline p
Depression - Pipeline Review, H1 2013 Report Features Players such as Elan, Pfizer and AstraZeneca
M2 - Thu May 02, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7r46cb/depression) has announced the addition of the "Depression - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Depression - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Depression - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression pro
Ischemic Stroke - Pipeline Review, H1 2013 Report Profiles Players such as Eli Lilly and Company and SynZyme Technologies, LLC
M2 - Mon Apr 29, 11:16AM CDT
Research and Markets has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by c
Psychosis - Pipeline Review, H1 2013
M2 - Thu Mar 28, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/88bbf3/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Scope - A snapshot of the global therapeutic scenario for Psychosis. - A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Cov
Stroke - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nswlxr/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. Scope - A snapshot of the global therapeutic scenario for Stroke. - A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the
Why Chelsea Therapeutics International Ltd. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - 1 hr ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Chelsea Therapeutics , a biopharmaceutical...
Caregivers of People with Schizophrenia Need Support, Not Stigma
Business Wire - Thu May 01, 8:01AM CDT
Despite growing awareness of mental illness nationally, serious mental illnesses, such as schizophrenia, continue to be associated with significant stigma - not just for the person directly affected, but also for the caregiver.(1,2) Caregivers act as advocates, collaborate with treatment team members and often are the main support in the daily life of their loved one with schizophrenia.(3,4) However, results of a recent survey show that caregivers have experienced emotional burden and social isolation as a result of caring for their loved one.
FDA Accepts for Review Otsuka Pharmaceutical and Lundbeck's Supplemental New Drug Application to Expand Abilify Maintena(R) (aripiprazole) Labeling
Business Wire - Wed Apr 30, 8:02AM CDT
Otsuka America Pharmaceutical, Inc. (OAPI) and H. Lundbeck A/S (Lundbeck) today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for the proposed expanded labeling of Abilify Maintena (aripiprazole) for extended-release injectable suspension to support broader use of the drug for treatment of patients in the acute phase of schizophrenia. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of December 7, 2014 to complete its review.
Eli Lilly Beats on Earnings & Revs, Confirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:40PM CST
2014 will be a challenging year for Eli Lilly with two major products - Cymbalta and Evista - facing generic competition this year.
Allergan Slips on Restasis Challenge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 12:50PM CST
Although Allergan's shares slipped slightly on the news regarding Actavis' ANDA, we do not expect generic competition to enter the market any time soon.
The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
PR Newswire - Wed Dec 18, 7:00AM CST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that successfully treat patients with mild and moderate disease, including market leaders GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination Advair/Seretide/Adoair and Merck's leukotriene inhibitor Singulair (montelukast). These leading agents are already beginning to face generic erosion that will lead their sales to decline.
Mood-Altering News From the Pharma Space
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Dec 13, 9:10AM CST
As a longtime critic of Eli Lilly 's R&D and clinical trial management, I can't say I was surprised to see the news that yet another phase 3 drug candidate failed -- this time it was edivoxetine in depression. That stings all the more with...
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psychiatric Disorders - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/pscmg6/psychiatric) has announced the addition of the "Psychiatric Disorders - Pipeline Review, H2 2013" report to their offering. 'Psychiatric Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Scope - A snapshot of the global therapeutic scenario for Psychiatric Disorders. - A review of the Psychiatric Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychiatric Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Psychiatric Disorders. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Psychiatric Disorders pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Boehringer Ingelheim GmbH Dainippon Sumitomo Pharma Co., Ltd. Samyang Corporation H Lundbeck A/S AVANIR Pharmaceuticals Corcept Therapeutics Incorporated Suven Life Sciences Ltd. Angelini Group Snowdon Inc. Critical Pharmaceuticals Limited CoLucid Pharmaceuticals, Inc. GP Pharm, S.A. PsychoGenics, Inc. Omeros Corporation Edison Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ps...sychiatric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Major Depressive Disorder - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vssm4r/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2013" report to their offering. 'Major Depressive Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Major Depressive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Major Depressive Disorder. Scope - A snapshot of the global therapeutic scenario for Major Depressive Disorder. - A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Major Depressive Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson F. Hoffmann-La Roche Ltd. AstraZeneca PLC Eli Lilly and Company Alkermes, Inc. Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Neurocrine Biosciences, Inc. Gedeon Richter Plc. H Lundbeck A/S Laboratoires Pierre Fabre SA Les Laboratoires Servier Shire Plc OPKO Health, Inc. Neuralstem, Inc. Suven Life Sciences Ltd. e-Therapeutics plc Intas Pharmaceuticals Ltd. Angelini Group and many more... For more information visit http://www.researchandmarkets.com/research/vs...depressive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Alzheimer's Disease Report - Pipeline Review
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d9h2c7/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2013" report to their offering. 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Scope - A snapshot of the global therapeutic scenario for Alzheimer's Disease. - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Alzheimer's Disease Therapeutics Development - Click the link below to view the full list of companies - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - United Biomedical, Inc. - Taisho Pharmaceutical Co., Ltd. - Euroscreen S.A. - Applied NeuroSolutions, Inc. - Avineuro Pharmaceuticals, Inc. - Panacea Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - Novartis AG - Isotechnika Pharma Inc. - Samyang Corporation - Aphios Corporation - Alzhyme Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - H Lundbeck A/S - Jeil Pharmaceutical Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier For more information visit http://www.researchandmarkets.com/research/d9h2c7/alzheimers
Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Parkinson's Disease - Pipeline Review, H2 2013 Report Features Players such as Fabre-Kramer Pharmaceuticals, Inc. and Novartis AG
M2 - Wed Aug 07, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fx4cdq/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Parkinson's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Parkinson's Disease. - A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Parkinson's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Amicus Therapeutics, Inc. AstraZeneca PLC Biogen Idec Inc. Boehringer Ingelheim GmbH Curemark, LLC Dart NeuroScience LLC e-Therapeutics plc Elan Corporation, plc GlaxoSmithKline plc H Lundbeck A/S Indus Biotech Private Limited Jeil Pharmaceutical Co., Ltd. KineMed, Inc. Labtec GmbH Merck & Co., Inc. OPKO Health, Inc. Pharmagenesis, Inc. QR Pharma, Inc. Raptor Pharmaceuticals Corp. reMYND Sanofi-Aventis Snowdon Inc. Takeda Pharmaceutical Company Limited UCB Group ViaCord Wellstat Therapeutics Corporation XenoPort, Inc. For more information visit http://www.researchandmarkets.com/research/fx4cdq/parkinsons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psychosis - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and Clera Inc.
M2 - Tue Aug 06, 12:02PM CDT
Research and Markets (http://www.researchandmarkets.com/research/plc8gk/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Psychosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Psychosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Addex Pharmaceuticals Clera Inc. Evotec Aktiengesellschaft H Lundbeck A/S Newron Pharmaceuticals S.p.A. Reviva Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/plc8gk/psychosi About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
General Anxiety Disorder - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bhjrl/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H1 2013" report to their offering. 'General Anxiety Disorder - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline p
Depression - Pipeline Review, H1 2013 Report Features Players such as Elan, Pfizer and AstraZeneca
M2 - Thu May 02, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7r46cb/depression) has announced the addition of the "Depression - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Depression - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Depression - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression pro
Ischemic Stroke - Pipeline Review, H1 2013 Report Profiles Players such as Eli Lilly and Company and SynZyme Technologies, LLC
M2 - Mon Apr 29, 11:16AM CDT
Research and Markets has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by c
Psychosis - Pipeline Review, H1 2013
M2 - Thu Mar 28, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/88bbf3/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Scope - A snapshot of the global therapeutic scenario for Psychosis. - A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Cov
Stroke - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nswlxr/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Stroke - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. Scope - A snapshot of the global therapeutic scenario for Stroke. - A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the
